`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`
`AQUESTIVE THERAPEUTICS, INC.,
`Petitioner,
`
`v.
`
`ICOS CORPORATION,
`Patent Owner.
`
`__________________
`
`Case IPR2018-01183
`Patent No. 6,943,166
`__________________
`
`
`PATENT OWNER’S MANDATORY NOTICES
`
`
`
`
`
`Case No. IPR2018-01183
`Patent No. 6,943,166
`
`Pursuant to 37 C.F.R. § 42.8, Patent Owner ICOS Corporation provides the
`
`following mandatory notices.
`
`I.
`
`Real Party-in-Interest - 37 C.F.R. § 42.8(b)(1)
`
`The real parties-in-interest are ICOS Corporation and Eli Lilly and
`
`Company.
`
`II. Related Matters - 37 C.F.R. § 42.8(b)(2)
`
`• Eli Lilly & Co. v. Accord Healthcare, Inc., No. 1:16-cv-01352 (E.D. Va.);
`
`• Eli Lilly & Co. v. Actavis Laboratories UT, Inc., No. 1:16-cv-01119 (E.D.
`
`Va.);
`
`• Eli Lilly & Co. v. Ajanta Pharma, Ltd., No. 1:17-cv-00020 (E.D. Va.);
`
`• Eli Lilly & Co. v. Alembic Pharmaceuticals Ltd., No. 1:16-cv-01120 (E.D.
`
`Va.);
`
`• Eli Lilly & Co. v. Apotex, Inc., No. 3:16-cv-00941 (E.D. Va.);
`
`• Eli Lilly & Co. v. Aurobindo Pharma Ltd., No. 1:16-cv-01121 (E.D. Va.);
`
`• Eli Lilly & Co. v. Cipla Ltd., No. 1:16-cv-01208 (E.D. Va.);
`
`• Eli Lilly & Co. v. Mylan Pharms. Inc., No. 1:16-cv-01122 (E.D. Va.);
`
`• Eli Lilly & Co. v. Sun Pharm. Indus., Ltd., No. 2:16-cv-00518 (E.D. Va.);
`
`• Eli Lilly & Co. v. Teva Pharms. USA Inc., No. 2:16-cv-00519 (E.D. Va.);
`
`• Eli Lilly & Co. v. Zydus Pharms. (USA) Inc., No. 2:16-cv-00520 (E.D. Va.);
`
`1
`
`
`
`• Eli Lilly & Co. v. Hetero USA, Inc., No. 2:17-cv-01951 (D.N.J.);
`
`Case No. IPR2018-01183
`Patent No. 6,943,166
`
`
`• Eli Lilly & Co. v. Dr. Reddy’s Laboratories, Inc., No. 3:17-cv-02541
`
`(D.N.J.);
`
`• Eli Lilly & Co. v. Macleods Pharma USA, Inc., No. 3:17-cv-05087 (D.N.J.);
`
`• Eli Lilly & Co. v. Glenmark Pharms. Ltd., No. 2:17-cv-07024 (D.N.J.);
`
`• Eli Lilly & Co. v. Unichem Labs., Ltd., No. 2:17-cv-13312 (D.N.J.);
`
`• Eli Lilly & Co. v. Lupin Ltd., No. 1:18-cv-00055 (D. Del.);
`
`• Eli Lilly & Co. v. Sunshine Lake Pharma Co., Ltd., No. 2:18-cv-05765
`
`(D.N.J.);
`
`• Eli Lilly & Co. v. Amneal Pharmaceuticals LLC, No. 2:18-cv-09071
`
`(D.N.J.);
`
`• IntelGenX Corp. v. ICOS Corp., IPR2016-00678;
`
`• Mylan Pharmaceuticals Inc. v. ICOS Corp., IPR2017-00323;
`
`• MonoSol RX, LLC v. ICOS Corp., IPR2017-00412;
`
`• Dr. Reddy’s Laboratories, Inc. v. ICOS Corp., IPR2017-01757; and
`
`• Argentum Pharms. LLC v. ICOS Corp., IPR20107-01762.
`
`III. Lead and Back-up Counsel - 37 C.F.R. § 42.8(b)(3)
`
`Patent Owner designates the following lead and back-up counsel:
`
`Lead Counsel
`
`Mark J. Feldstein (Reg. No. 46,693)
`FINNEGAN, HENDERSON, FARABOW,
`
`2
`
`
`
`Case No. IPR2018-01183
`Patent No. 6,943,166
`
`
` GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Telephone: (202) 408-4092
`Facsimile:
`(202) 408-4400
`Email: mark.feldstein@finnegan.com
`Joshua L. Goldberg (Reg. No. 59,369)
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Telephone: (202) 408-6092
`Facsimile:
`(202) 408-4400
`Email: joshua.goldberg@finnegan.com
`Yieyie Yang (Reg. No. 71,923)
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Telephone: (202) 216-5170
`Facsimile:
`(202) 408-4400
`Email: yieyie.yang@finnegan.com
`Charles W. Mitchell (Reg. No. 73,228)
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Telephone: (202) 408-4361
`Facsimile:
`(202) 408-4400
`Email: charles.mitchell@finnegan.com
`Mark J. Stewart (Reg. No. 43,936)
`Eli Lilly and Company
`Lilly Corporate Center
`Indianapolis, IN 46285
`Telephone: (317) 276-0280
`Facsimile:
`(317) 276-3861
`
`3
`
`First Back-up
`Counsel
`
`Additional Back-up
`Counsel
`
`Additional Back-up
`Counsel
`
`Additional Back-up
`Counsel
`
`
`
`Additional Back-up
`Counsel
`
`Additional Back-up
`Counsel
`
`Case No. IPR2018-01183
`Patent No. 6,943,166
`
`
`Email: stewart_mark@lilly.com
`Dan L. Wood (Reg. No. 48,613)
`Eli Lilly and Company
`Lilly Corporate Center
`Indianapolis, IN 46285
`Telephone: (317) 277-3366
`Facsimile:
`(317) 276-3861
`Email: wood_dan_l@lilly.com
`Gerald P. Keleher (Reg. No. 43,707)
`Eli Lilly and Company
`Lilly Corporate Center
`Indianapolis, IN 46285
`Telephone: (317) 276-3964
`Facsimile:
`(317) 276-0894
`Email: keleher_gerald@lilly.com
`
`
`IV. Service Information - 37 C.F.R. § 42.8(b)(4)
`
`Patent Owner also consents to electronic service by email at the email
`
`addresses listed in the previous section and ICOS-IPRs@finnegan.com.
`
`Date: June 28, 2018
`
`
`
`Respectfully submitted,
`
`
`
`By: /Joshua L. Goldberg/
`Joshua L. Goldberg, Reg. No. 59,369
`
`
`
`Counsel for Patent Owner
`ICOS Corporation
`
`
`
`4
`
`
`
`Case No. IPR2018-01183
`Patent No. 6,943,166
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of the foregoing Patent Owner’s
`
`
`
`Mandatory Notices was served electronically via email on June 28, 2018, in its
`
`
`
`
`
`By: /William Esper/
`William Esper
`Legal Assistant
`
`Finnegan, Henderson, Farabow,
`Garrett & Dunner, LLP
`
`
`
`entirety on the following:
`
`Harold H. Fox
`hfox@steptoe.com
`
`Gretchen P. Miller
`gmiller@steptoe.com
`
`
`Date: June 28, 2018
`
`
`
`
`
`